Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients.
Neutralising antibodies develop in 15% of interferon-beta (IFNbeta)-treated patients, causing the reduction of the clinical effects of the treatment. This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. In conclusion, our data suggest the use of GA in NAb-positive patients.
Capobianco
Marco
M
Centro di Riferimento Regionale Sclerosi Multipla e Neurobiologia Clinica, AOU S. Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, TO, Italy. sclerosi.multipla@sanluigi.piemonte.it
Rizzo
Annalisa
A
Malucchi
Simona
S
Sperli
Francesca
F
Di Sapio
Alessia
A
Oggero
Alessandra
A
Zaffaroni
Mauro
M
Ghezzi
Angelo
A
Bertolotto
Antonio
A
D000906:Antibodies / Q000097:blood / Q000187:drug effects* / Q000276:immunology; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D004351:Drug Resistance / Q000187:drug effects / Q000276:immunology; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016899:Interferon-beta / Q000276:immunology* / Q000494:pharmacology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D055502:Secondary Prevention; D016019:Survival Analysis; D013995:Time; D016896:Treatment Outcome
D000906:Antibodies; D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta